- Home
- CRBP vs KNDI Comparison
CRBP vs KNDI Comparison
Compare CRBP & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- KNDI
- Stock Information
- Founded
- CRBP 2009
- KNDI 2002
- Country
- CRBP United States
- KNDI China
- Employees
- CRBP N/A
- KNDI N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- KNDI Auto Manufacturing
- Sector
- CRBP Health Care
- KNDI Consumer Discretionary
- Exchange
- CRBP Nasdaq
- KNDI Nasdaq
- Market Cap
- CRBP 96.5M
- KNDI 96.3M
- IPO Year
- CRBP N/A
- KNDI N/A
- Fundamental
- Price
- CRBP $8.22
- KNDI $1.20
- Analyst Decision
- CRBP Strong Buy
- KNDI
- Analyst Count
- CRBP 10
- KNDI 0
- Target Price
- CRBP $53.56
- KNDI N/A
- AVG Volume (30 Days)
- CRBP 214.0K
- KNDI 109.2K
- Earning Date
- CRBP 08-05-2025
- KNDI 08-15-2025
- Dividend Yield
- CRBP N/A
- KNDI N/A
- EPS Growth
- CRBP N/A
- KNDI N/A
- EPS
- CRBP N/A
- KNDI N/A
- Revenue
- CRBP N/A
- KNDI $127,569,613.00
- Revenue This Year
- CRBP N/A
- KNDI N/A
- Revenue Next Year
- CRBP $150.03
- KNDI N/A
- P/E Ratio
- CRBP N/A
- KNDI N/A
- Revenue Growth
- CRBP N/A
- KNDI 3.21
- 52 Week Low
- CRBP $4.64
- KNDI $0.89
- 52 Week High
- CRBP $61.90
- KNDI $2.07
- Technical
- Relative Strength Index (RSI)
- CRBP 54.23
- KNDI 52.54
- Support Level
- CRBP $7.26
- KNDI $1.09
- Resistance Level
- CRBP $7.90
- KNDI $1.17
- Average True Range (ATR)
- CRBP 0.53
- KNDI 0.07
- MACD
- CRBP -0.01
- KNDI 0.01
- Stochastic Oscillator
- CRBP 78.59
- KNDI 61.23
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.